These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 19164435)

  • 1. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.
    Lin Y; Jiang T; Zhou K; Xu L; Chen B; Li G; Qiu X; Jiang T; Zhang W; Song SW
    Neuro Oncol; 2009 Oct; 11(5):468-76. PubMed ID: 19164435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma.
    Gállego Pérez-Larraya J; Paris S; Idbaih A; Dehais C; Laigle-Donadey F; Navarro S; Capelle L; Mokhtari K; Marie Y; Sanson M; Hoang-Xuan K; Delattre JY; Mallet A
    Cancer; 2014 Dec; 120(24):3972-80. PubMed ID: 25139333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of serum levels and tissue expression of two genes IGFBP-2 and IGFBP-3 act as potential biomarker for predicting the progression and survival in patients with glioblastoma multiforme.
    Abdolhoseinpour H; Mehrabi F; Shahraki K; Khoshnood RJ; Masoumi B; Yahaghi E; Goudarzi PK
    J Neurol Sci; 2016 Jul; 366():202-206. PubMed ID: 27288807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma IGFBP-2 levels after postoperative combined radiotherapy and chemotherapy predict prognosis in elderly glioblastoma patients.
    Han S; Meng L; Han S; Wang Y; Wu A
    PLoS One; 2014; 9(4):e93791. PubMed ID: 24690948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma.
    Santosh V; Arivazhagan A; Sreekanthreddy P; Srinivasan H; Thota B; Srividya MR; Vrinda M; Sridevi S; Shailaja BC; Samuel C; Prasanna KV; Thennarasu K; Balasubramaniam A; Chandramouli BA; Hegde AS; Somasundaram K; Kondaiah P; Rao MR
    Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1399-408. PubMed ID: 20501753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between concentrations of IGF-1 and IGFBP-3 and preoperative depression risk, and effect of psychological intervention on outcomes of high-grade glioma patients with preoperative depression in a 2-year prospective study.
    Wang Y; Huang M; Jiao JT; Wu YL; Ouyang TH; Huang J; Liu SS; Li CL
    Med Oncol; 2014 May; 31(5):921. PubMed ID: 24668415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil/Lymphocyte Ratio Is an Independent Prognostic Factor in Elderly Patients with High-Grade Gliomas.
    Gan Y; Zhou X; Niu X; Li J; Wang T; Zhang H; Yang Y; Liu Y; Mao Q
    World Neurosurg; 2019 Jul; 127():e261-e267. PubMed ID: 30898756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma.
    Yue X; Lan F; Hu M; Pan Q; Wang Q; Wang J
    J Neurosurg; 2016 Jan; 124(1):122-8. PubMed ID: 26230475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan.
    Farina P; Tabouret E; Lehmann P; Barrie M; Petrirena G; Campello C; Boucard C; Graillon T; Girard N; Chinot O
    J Neurooncol; 2017 May; 132(3):433-437. PubMed ID: 28265824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade.
    Elmlinger MW; Deininger MH; Schuett BS; Meyermann R; Duffner F; Grote EH; Ranke MB
    Endocrinology; 2001 Apr; 142(4):1652-8. PubMed ID: 11250947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploratory investigation of eight circulating plasma markers in brain tumor patients.
    Ilhan-Mutlu A; Wagner L; Widhalm G; Wöhrer A; Bartsch S; Czech T; Heinzl H; Leutmezer F; Prayer D; Marosi C; Base W; Preusser M
    Neurosurg Rev; 2013 Jan; 36(1):45-55; discussion 55-6. PubMed ID: 22763625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor binding protein-2 regulates β-catenin signaling pathway in glioma cells and contributes to poor patient prognosis.
    Patil SS; Gokulnath P; Bashir M; Shwetha SD; Jaiswal J; Shastry AH; Arimappamagan A; Santosh V; Kondaiah P
    Neuro Oncol; 2016 Nov; 18(11):1487-1497. PubMed ID: 27044294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A panel of four cytokines predicts the prognosis of patients with malignant gliomas.
    Lin Y; Zhang G; Zhang J; Gao G; Li M; Chen Y; Wang J; Li G; Song SW; Qiu X; Wang Y; Jiang T
    J Neurooncol; 2013 Sep; 114(2):199-208. PubMed ID: 23748572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. STAT-1 expression is regulated by IGFBP-3 in malignant glioma cells and is a strong predictor of poor survival in patients with glioblastoma.
    Thota B; Arimappamagan A; Kandavel T; Shastry AH; Pandey P; Chandramouli BA; Hegde AS; Kondaiah P; Santosh V
    J Neurosurg; 2014 Aug; 121(2):374-83. PubMed ID: 24878287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma.
    Mair MJ; Ilhan-Mutlu A; Pajenda S; Kiesel B; Wöhrer A; Widhalm G; Dieckmann K; Marosi C; Wagner L; Preusser M; Berghoff AS
    Cancer Immunol Immunother; 2021 Dec; 70(12):3643-3650. PubMed ID: 33956203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum beta2-microglobulin acts as a biomarker for severity and prognosis in glioma patients: a preliminary clinical study.
    Liu ZY; Tang F; Wang J; Yang JZ; Chen X; Wang ZF; Li ZQ
    BMC Cancer; 2024 Jun; 24(1):692. PubMed ID: 38844902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma.
    Lan F; Qing Q; Pan Q; Hu M; Yu H; Yue X
    Cell Oncol (Dordr); 2018 Feb; 41(1):25-33. PubMed ID: 29076027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme.
    Greenfield JP; Jin DK; Young LM; Christos PJ; Abrey L; Rafii S; Gutin PH
    Neurosurgery; 2009 May; 64(5):819-26; discussion 826-7. PubMed ID: 19404145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment.
    Alan O; Telli TA; Basoğlu T; Arikan R; Demircan NC; Ercelep O; Bozkurt S; Atasoy BM; Dane F; Yumuk PF
    Clin Neurol Neurosurg; 2020 Sep; 196():105976. PubMed ID: 32531614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.